PREDICT is an online prognostication and treatment benefit tool designed to help clinicians and patients make informed decisions about treatment following breast cancer surgery. The survival estimates, presented both with and without adjuvant therapy (hormone therapy and chemotherapy), are provided for 5 and 10 years following surgery. The model was developed by a team of researchers from Cambridge, led by Professor Gordon Wishart, and involved colleagues from the Cambridge Breast Unit, University of Cambridge Department of Oncology and the Eastern Cancer Information and Registration Centre (ECRIC).
The model is based on UK cancer registry data and includes mode of detection for the first time. For further information about the model please review the papers published in Breast Cancer Research and the European Journal of Surgical Oncology in 2010.
In October 2011 a new version of PREDICT, including HER2 and the benefit of trastuzumab, was launched on the PREDICT website (www.predict.nhs.uk). This is the first prognostic model based on clinical and pathological factors to include HER2 status.